Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Barclays PLC (BCS) vs Summit Therapeutics Inc (SMMT) Price & Performance

Barclays PLCTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Barclays PLC vs Summit Therapeutics Inc — how do they compare? Barclays PLC trades at $27.98 (market cap $93.87B), while Summit Therapeutics Inc trades at $15.48 (market cap $12.06B). The key difference: Barclays PLC is far larger — about 7.8× Summit Therapeutics Inc's market cap, and Barclays PLC pays a 2.19% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

BCSSMMT
Market Cap
$93.87B$12.06B
Sector
FinancialsHealth
52-Week High
$28.56$26.98
52-Week Low
$19.36$12.55
Dividend Yield
2.19%
Enterprise Value
$11.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Barclays PLC

Barclays PLC (BCS) trades at $27.98, up 0.18% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals, including a P/E of 10.68, P/B of 0.88, and net income margin of 25.51%, with Q2 2026 EPS beating estimates at $0.90. Recent news highlights a 17% profit jump in H1 2026 but also a securities class action investigation, creating mixed sentiment.

The outlook is cautiously optimistic, supported by earnings beats and a 68% analyst buy rating, but risks include cost pressures, legal scrutiny, and market volatility. Upside potential hinges on sustained profit growth and efficient cost management amid economic uncertainties.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments

Read more on BCS

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT